Services › Commercial Compliance
Commercial Compliance

Effective compliance programs — designed, built, and proven.

Programs built on the OIG’s seven elements and the DOJ’s three fundamental questions — designed, implemented, operated, trained, monitored, audited, and remediated across the full life-sciences life cycle.

An executive boardroom set for a governance and audit-committee meeting

TRESTLE's founder-led commercial compliance practice is built on the OIG's seven elements of an effective compliance program and the DOJ's three fundamental questions that federal prosecutors use to evaluate them. We design, implement, operate, train, monitor, audit, and remediate commercial compliance programs across the life sciences life cycle — from pre-clinical and pre-launch through commercial-stage and post-CIA remediation.

What we do

End-to-end commercial compliance for life sciences

  • Program design, build-out, and gap remediation aligned to the OIG seven elements
  • Written standards, policies, SOPs, and code of conduct for commercial operations
  • Training curricula, live workshops, and role-based competency programs
  • Monitoring & auditing plans, sample-based reviews, and finding-remediation tracking
  • Speaker programs, HCP engagements, advisory boards, and grants oversight
  • Fair-market-value (FMV) rates and documentation — anchored to Stark §411.351 (see TRESTLE FMV™)
  • Disciplinary framework, hotline & investigation SOPs, and corrective-action workflows
  • Board and audit-committee reporting cadence and materials
  • Post-CIA / IRO remediation, monitor readiness, and reportable-events workflows
DOJ Evaluation of Corporate Compliance Programs (2024)

Three fundamental questions.

The Criminal Division uses three questions to evaluate every corporate compliance program. TRESTLE builds programs to answer — and evidence — each one.

Question 01
Is the compliance program well designed?
Question 02
Is it being applied earnestly and in good faith — adequately resourced and empowered to function effectively?
Question 03
Does the program work in practice?

The OIG seven elements of an effective compliance program

Anchored to OIG GCPG (2023) and industry-specific guidance
01
Written policies, procedures & standards

Code of conduct, commercial SOPs, and role-specific policies with a documented review cycle.

02
Compliance leadership & oversight

Empowered CCO, board and audit-committee oversight, and cross-functional compliance committee.

03
Training & education

New-hire, annual, and role-based training with attestation, competency checks, and remediation for gaps.

04
Open lines of communication

Confidential hotline, non-retaliation policy, escalation SOPs, and management-by-walking-around cadence.

05
Monitoring, auditing & risk assessment

Annual risk assessment, monitoring plan, sample-based audits, and evidence-preservation practices.

06
Enforcement & discipline

Consistent discipline matrix, HR-Compliance interlock, and documented enforcement rationale.

07
Response & corrective action

Investigation SOPs, root-cause analysis, remediation tracking, and reportable-events workflow.

Design → Implement → Operate → Train → Monitor → Audit → Remediate

1
Design
2
Implement
3
Operate
4
Train
5
Monitor
6
Audit
7
Remediate
Pre-clinical & discovery

Foundational scaffolding

Right-sized code of conduct, conflict-of-interest and grants policies, HCP-engagement guardrails, and IP/privacy hygiene — sized to a small team without over-building.

Pre-launch & first product

Launch-ready program build-out

Commercial SOPs, sales & medical-affairs training, promotional review, speaker programs, advisory boards, FMV, PDMA, sunshine reporting, and monitoring plan — live before first patient.

Commercial-stage

Operate, monitor & audit

Steady-state monitoring, annual auditing, board reporting, investigations, discipline, and continuous improvement — with objective evidence for every DOJ question.

Post-CIA / M&A prep

Remediation & diligence readiness

CIA compliance, IRO coordination, reportable-events workflow, and buyer-side or seller-side diligence packages that hold up under scrutiny.

Next Step

Discuss your commercial compliance priorities.

Bring the launch, monitoring, diligence, or program question in front of you. We’ll help define a practical and defensible path forward.